New Single-Dose flu drug shows promise in kids trial

NCT ID NCT07095257

Completed Disease control Sponsor: Nanjing Zenshine Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new flu medicine called ZX-7101A in 169 children aged 2 to 11. The medicine was given as a single oral dose, and researchers compared it to a standard 5-day treatment (oseltamivir). The main goal was to check safety and how well it relieved flu symptoms. The trial is complete, but full results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZX-7101A (an antiviral drug for influenza)
What this could lead to: If successful, ZX-7101A could offer a new single-dose treatment option for children with the flu, potentially simplifying care compared to current multi-day regimens.
What could go wrong: This is a completed phase 3 trial, but results are not yet published. The drug may not prove safer or more effective than existing treatments like oseltamivir, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY VIRAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY VIRAL INFECTION

Contacts and locations

Locations

Children's Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China
West China Second University Hospital, Sichuan University

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.